REG - ValiRx PLC - Result of AGM and Appointment of Joint Broker

ValiRxAnnouncement

30/06/2022 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd8793Qa&default-theme=true

RNS Number : 8793Q  ValiRx PLC  30 June 2022

30 June 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Result of AGM and Appointment of Joint Broker

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health announces that at its
Annual General Meeting ("AGM") held earlier today, all resolutions were duly
passed. Details of the votes received will be available shortly on the
Company's website.

As announced on 7 June 2022, Kevin Alexander has ceased to be a director of
the Company following the conclusion of the AGM.

Appointment of Joint Broker

Further to the announcement made today in relation to the Company's fundraise,
the Company is pleased to announce the appointment of Turner Pope Investments
(TPI) Limited as joint broker to the Company with immediate effect.

 

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                              Tel: +44 (0) 2476 796496

                                                         www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                                   Suzanne.Dilly@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)        Tel: +44 (0) 20 7213 088

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities Limited (Joint Broker)                Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (TPI) Limited  (Joint Broker)   Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCXBLFXLQLEBBZ